Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 08, 2018 9:18:09 AM
The biggest problems with this stock IMO is:
-they always have low cash on hand.
-the cash burn rate is high (not super high), but still forces negative cash flow.
-due to the above the need for the owners to keep buying stock to fund the extra cash needs, and leads to the potential for significant dilution.
-the board they are on, placement and news reach keeps both good news somewhat hidden from the majority of potential investors.
The biggest pluses IMO are:
-They have real technology that is not a scam and has significant potential in areas of critical medical needs.
-They have accomplished most of what they say they are going to do.
-They have used their developments to support their technology to produce viable products.
-They have real earnings from the marketing branches of their products in cell technology and skin care as separate entities.
-due to the above, they are one of the few developmental/clinical stage biotech companies that have any revenue generating arm at all. Thus some of their cash burn is funded through division earnings and they additionally gain valuable marketing experience and contacts.
-They have a multitude of patents, some more valuable than others. Patents are costly to get and maintain, but add to a companies intellectual property value and can be the key to future success or buyout value.
-their clinical stage I and II studies are done through a world renowned neurological research facility. (no company that has scam technology would be able to get their foot in the door with such reputable organizations)
I don't know if any of this helps, but that is my take on ISCO.
Recent ISCO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:05:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:00:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:00:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 06:18:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 06:17:20 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/27/2023 04:27:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:01:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 06:20:54 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM